Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.

[1]  Haroon,et al.  A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes , 2022, Medicine.

[2]  Jay W. Wright,et al.  BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence , 2012, PloS one.

[3]  S. Kaye,et al.  The role of targeted therapy in ovarian cancer. , 2011, European journal of cancer.

[4]  A. Skytte,et al.  Identification of BRCA1‐deficient ovarian cancers , 2011, Acta obstetricia et gynecologica Scandinavica.

[5]  D. Matei,et al.  Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Green,et al.  The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression , 2011, Virchows Archiv.

[7]  K. Odunsi,et al.  Expression of Poly (Adenosine Diphosphate-Ribose) Polymerase and p53 in Epithelial Ovarian Cancer and Their Role in Prognosis and Disease Outcome , 2011, International Journal of Gynecological Pathology.

[8]  M. Toulmonde,et al.  A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. O’Shaughnessy,et al.  Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer , 2010, Clinical Cancer Research.

[10]  G. Mills,et al.  Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Lorusso,et al.  Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal , 2010, Cancer and Metastasis Reviews.

[12]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[13]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  S. Gayther,et al.  The Contribution of BRCA1 and BRCA2 to Ovarian Cancer , 2009, Molecular oncology.

[15]  R. Kennedy,et al.  BRCA1 and implications for response to chemotherapy in ovarian cancer. , 2009, Gynecologic oncology.

[16]  B. Vanderhyden,et al.  Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Al-Attar,et al.  Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies? , 2008, Clinical Cancer Research.

[18]  R. Soslow,et al.  Histologic subtypes of ovarian carcinoma: an overview. , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[19]  P. Rolland,et al.  Loss of IFNγ Receptor Is an Independent Prognostic Factor in Ovarian Cancer , 2007, Clinical Cancer Research.

[20]  M. Bernardini,et al.  Adenomyosis is Associated With Myometrial Invasion by FIGO 1 Endometrial Adenocarcinoma , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  Jacqueline A. Hall,et al.  Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies , 2006, British Journal of Cancer.

[22]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[23]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[24]  Xuelin Huang,et al.  Validation of tissue microarray technology in ovarian carcinoma , 2004, Modern Pathology.

[25]  B. Modan,et al.  Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[27]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[28]  G. Lenoir,et al.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region , 1998, Oncogene.

[29]  G. de Murcia,et al.  Importance of Poly(ADP-ribose) Polymerase and Its Cleavage in Apoptosis , 1998, The Journal of Biological Chemistry.

[30]  T. Bjørge,et al.  Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 , 1998, International journal of cancer.

[31]  M. Markman,et al.  Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Shibata,et al.  Analysis of DNA sequences in forty-year-old paraffin-embedded thin-tissue sections: a bridge between molecular biology and classical histology. , 1988, Cancer research.

[33]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[34]  A. Chen,et al.  PARP inhibitor treatment in ovarian and breast cancer. , 2011, Current problems in cancer.

[35]  P. Das,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[36]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[37]  E. Friedman,et al.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  David C. Corney,et al.  Role of p53 and Rb in ovarian cancer. , 2008, Advances in experimental medicine and biology.

[39]  P. Rolland,et al.  Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  H. Brustmann.  Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome. , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.